Dr. Verstovsek Discusses Immunotherapy in Myelofibrosis
Srdan Verstovsek, MD, PhD, the University of Texas MD Anderson Cancer Center, discusses immunotherapy in myelofibrosis.
Srdan Verstovsek, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses immunotherapy in myelofibrosis.
Little is known about regulation in immune control in myelofibrosis, as well as how or whether this therapy will have any clinical applicability, Verstovsek says.
There is currently a study underway investigating nivolumab; Verstovsek and his colleagues are exploring the activity, as well as the biology of the disease, he says. Samples are looked at before therapy, and during therapy, to determine the underlying problem and how it is affected by therapy.
In all, Verstovsek believes there may be a clinical benefit with immunotherapies for the treatment of myelofibrosis.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
